A Phase 2 interventional study of 0.01% atropine ophthalmic drop in Vitreous Floaters, sponsored by Jeanette Du. Not yet recruiting at 1 site in United States. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2023-12-18.
Sponsored by Jeanette Du · Phase 2, Interventional, and Treatment
The objective of this study is to identify a potential pharmacologic option by assessing whether 0.01% atropine may be effective for treating bothersome floaters as measured by scores on a modified NEI VFQ-25.
740 studies on the registry are indexed under Eye Diseases; 117 are open to participants now.
This study's planned enrollment of 200 is above the median of 68 across 547 interventional studies indexed under Eye Diseases.
Browse Eye Diseases studies →This is the only study on the registry with Jeanette Du as lead sponsor.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Patients will apply 1 drop daily of atropine 0.01%
Drug: 0.01% atropine ophthalmic drop
0.01% atropine ophthalmic drop will be applied daily to the affected eye
Symptom improvement assessed by questionnaire
NEI VFQ-25 = National Eye Institute Visual Function Questionnaire
Time frame: Up to 2 months
Plan to share: No
No publications or documents are linked to this record.
This study is not yet recruiting, as verified in Dec 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.